Exosome Website - Headers (12)

* All times shown in EST

8:00 am Morning Speed Networking


Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

8:50 am Chair’s Opening Remarks


9:00 am Development of Therapeutic Exosomes

  • Linda Marbán Chief Executive Officer, Capricor Therapeutics, Inc.


  • Exosomes as a vaccine for COVID-19
  • CAP-1002 for the treatment of COVID-19

9:30 am Breakout Group Discussions: Exosomes as Viral Treatment Agents

Join a dedicated discussion group for this deep-dive session into your chosen topic. Discuss, share and debate in small breakout groups to find actionable takeaways and explore the innovative applications of exosomes as vaccine vectors. Progress to speed networking to continue making new connections!

How are we engineering exosomes for viral applications? What lessons have we learned to improve from the COVID-19 response?

Lessons learned from the COVID-19 response: What hurdles are stopping common exosome use in vaccine delivery & how can we overcome these?

The impact on business: How have the disruptive months of 2020 influenced the therapeutic landscape from a business perspective, & how can each stakeholder work together more effectively to accelerate therapeutic development?


Xandra Breakefield
, Professor, Neurology & Geneticist, Neurology & Radiology,
Harvard Medical School & Massachusetts General Hospital

10:30 am Therapeutic Implications of Complex Signaling Networks on Exosomes that Orchestrates the Development of Neuronal Circuits

  • Pranav Sharma Staff Scientist & Founder & Chief Scientific Officer, Scripps Research & Xosomix


  • Uncovering codes for content packaging into exosomes
  • Signaling networks on exosomes are continuously evolving during the development of neuronal circuits
  • Considering the therapeutic implications of the codes of packaging and evolution of exosome content

11:00 am Mesenchymal Stem Cell-Derived Extracellular Vesicles: Potential Modulators of the Immune System in Many Diseases

  • Bernd Giebel Group Leader, Institute for Transfusion Medicine, University Hospital Essen


  • According to controversial reports in the MSC field, especially since a phase III clinical trial failed to show clinical efficacy in MSC treated GvHD patients, we consider that MSC-EV preparations do not warrant therapeutic successes in general
  • At the experimental level we confirmed EVs prepared from MSCs of different donors can significantly vary in their immunomodulatory
    capabilities in vitro and in vivo and only a proportion shows the expected activities
  • Addressing several challenges to various aspects of scaling the MSC-EV production process

11:30 am Fundamental Aspects & Therapeutic Applications of Live Imaging of Single EV In Vivo

  • Guillaume van Niel Research Director, Université de Paris, Institute of Psychiatry & Neuroscience of Paris (IPNP), INSERM


  • Zebrafish embryo is a unique model organism to live-track endogenous and injected EV at vesicle scale through the whole organism up to their target cells
  • This organism provides a new pre-clinical model to test in vivo EVs that are harnessed as drug vehicles

12:00 pm Virtual Speed Networking


Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

12:30 pm Purification of EVs From Infected Cells for Diagnostic & Therapeutic Purposes


  • Learn about the purifications of EVs away from viruses
  • Use of large scale EV purification and characterization from drug treated cells
  • Uncover function of EVs on both infected and uninfected cells

12:45 pm Use of Stem Cell EVs as a Holistic Approach to CNS Repair

  • Heather Branscome Lead Biologist & PhD Candidate, American Type Culture Collection & George Mason University


  • Examine large scale isolation of stem cell (e.g. MSC, iPSC) EVs
  • Learn about the biochemical and physical characterization of stem cell EVs
  • Explore the in vitro functional analysis of stem cell EVs for CNS repair

1:00 pm MSC-NTF Exosomes as a Potential Treatment for Covid-19 ARDS & Related Disorders


  • Review of MSC and MSC-NTF exosome in vitro characteristics
  • Potential application MSC-NTF exosomes in COVID-ARDS and other related disorders
  • MSC-NTF vs. MSC exosomes preclinical data in ARDS model

1:30 pm Applying Placental MSC-Derived Exosomes to Treat Neurological Disorders & Congenital Diseases

  • Aijun Wang Associate Professor, Department of Surgery & Biomedical Engineering, University of California, Davis


  • Exploring the neuroprotective biology of exosomes and their applications for spina bifida, a structural birth defect
  • Understanding extracellular interactions of exosomes to improve targeted delivery and therapies
  • Improving yield and engineering exosomes for regenerative medicine applications

2:00 pm Virtual Speed Networking


Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!


2:30 pm Commercializing Novel Therapeutics with Strategic Collaborations

  • Richard Brudnick Chief Business Officer & Head of Strategy, Codiak Biosciences


  • Sourcing the right partner to meet your business goals
  • Discussing IP to protect therapeutic candidates
  • Overcoming contractual challenges for mutually beneficial partnerships and long-standing collaborations

3:00 pm Pre-Clinical Development of Exosome-Based Therapeutics: Challenges, Barriers & Opportunities

  • Joana Correia Executive Director & Chief Scientific Officer, Exogenus Therapeutics SA


  • Early establishment of scalable and controlled processes for the manufacturing of exosomes for clinical application
  • Challenges posed by the regulatory framework
  • Funding and strategic partnerships as drivers for the transition to clinical development

3:30 pm Panel Discussion: Commercialization, Partnerships & Regulation

  • Shaun Stapleton Vice President, Regulatory Affairs & Pharmacovigilance, ReNeuron Limited
  • Per Lundin Co-Founder & Chief Operating Officer, Evox Therpaeutics


  • What lessons have the leading companies in the field learned from their collaborations and submissions to date?
  • How can technology choice affect your commercial result?
  • Delving into recent regulatory conversations to inform trial design and, ultimately, maximize market access later in development

4:30 pm Chair’s Closing Remarks & End of 2nd Exosome Based Therapeutic Development Summit